TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03584490

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computerized Talking Touchscreen
Description: The intervention is a computerized talking touchscreen designed to aid people with low health literacy.~All Participants in both arms will complete a battery of health questionnaires. One group will complete questionnaires in traditional pen-and-paper format. The other group will receive the computerized talking touchscreen, which reads questions to participants on demand.
Study: NCT02428088

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasotraline
Description: Dasotraline 2 mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasotraline
Description: Dasotraline 4 mg once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Placebo once daily
Study: NCT01958099

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Education

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Study: NCT02902172

Intervention type: DRUG
Group type: OTHER
Intervention: Acetaminophen
Description: Blood pressure will be monitored during postpartum stay (typical 2 days) and then again at 1 week and 6 weeks (standard practice of care) with blood pressure measurements
Study: NCT00983164

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Antioxidant Supplementation
Description: antioxidant supplementation (vitamin E 800 mg, C 500 mg and zinc 40 mg) for 24 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Antioxidant Supplementation
Description: antioxidant supplementation (vitamin E 800 mg, C 500 mg and zinc 40 mg) for 24 weeks
Study: NCT00517933

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil Citrate
Description: Sildenafil citrate (20mg 3 times a day \[TID\] orally for 12 weeks followed by 20mg TID open-label sildenafil for an additional 12 weeks)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (20mg TID orally for 12 weeks followed by 20mg open-label sildenafil for 12 weeks)
Study: NCT02971930

Intervention type: BIOLOGICAL
Intervention: BAY94-9027
Description: Intravenous infusion of BAY94-9027

Intervention type: BIOLOGICAL
Intervention: BAY94-9027
Description: Intravenous infusion of BAY94-9027

Intervention type: BIOLOGICAL
Intervention: BAY94-9027
Description: Intravenous infusion of BAY94-9027
Study: NCT03523962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DuraPrep
Description: The iodine-based treatment intervention is an antiseptic solution comprised of iodine povacrylex (0.7% free iodine) in 74% isopropyl alcohol. 3M™ DuraPrep™ \[3M Health Care, St Paul, MN\], will be the commercial product used.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DuraPrep
Description: The iodine-based treatment intervention is an antiseptic solution comprised of iodine povacrylex (0.7% free iodine) in 74% isopropyl alcohol. 3M™ DuraPrep™ \[3M Health Care, St Paul, MN\], will be the commercial product used.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ChloraPrep
Description: The CHG intervention is an antiseptic solution comprised of 2% CHG in 70% isopropyl alcohol. ChloraPrep® \[CareFusion Inc., Leawood, KS, USA\] will be the product used.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ChloraPrep
Description: The CHG intervention is an antiseptic solution comprised of 2% CHG in 70% isopropyl alcohol. ChloraPrep® \[CareFusion Inc., Leawood, KS, USA\] will be the product used.
Study: NCT01022489

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation: rTMS
Description: 4 sessions of 13 minutes, with 2 sessions a day, at 20Hz frequency and at an intensity of 80% of rest motor threshold will be delivered

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (sham coil) treatment
Description: Sham coil treatment
Study: NCT02664194

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Proteus® Cooling System
Description: Intravascular hypothermia as an adjunctive method to primary percutaneous coronary intervention, adjunct hypothermia methods and parameters, using Proteus® Cooling System.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Proteus® Cooling System
Description: Intravascular hypothermia as an adjunctive method to primary percutaneous coronary intervention, adjunct hypothermia methods and parameters, using Proteus® Cooling System.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Primary Percutaneous Coronary Intervention
Description: Primary percutaneous coronary intervention

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Primary Percutaneous Coronary Intervention
Description: Primary percutaneous coronary intervention

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Primary Percutaneous Coronary Intervention
Description: Primary percutaneous coronary intervention
Study: NCT02955498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevikar tab. 10/40mg
Description: Reference drug: Sevikar tab. 10/40mg, 1T, single oral administration in the fasted state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevikar tab. 10/40mg
Description: Reference drug: Sevikar tab. 10/40mg, 1T, single oral administration in the fasted state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lodivikar tab. 5/40mg
Description: Test drug: Lodivikar tab 5/40mg, 1T, single oral administration in the fasted state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lodivikar tab. 5/40mg
Description: Test drug: Lodivikar tab 5/40mg, 1T, single oral administration in the fasted state
Study: NCT02332369

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Capsular Tension Ring
Study: NCT02979899

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TRC105
Description: TRC105 antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Votrient
Description: pazopanib

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Votrient
Description: pazopanib
Study: NCT02902172

Intervention type: DRUG
Group type: OTHER
Intervention: NSAID
Description: Blood pressure will be monitored during postpartum stay (typical 2 days) and then again at 1 week and 6 weeks (standard practice of care) with blood pressure measurements
Study: NCT01253226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2127399 (Tabalumab)
Description: Administered subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2127399 (Tabalumab)
Description: Administered subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2127399 (Tabalumab)
Description: Administered subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2127399 (Tabalumab)
Description: Administered subcutaneously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered subcutaneously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered subcutaneously
Study: NCT02499471

Intervention type: OTHER
Group type: OTHER
Intervention: Levothyroxine therapy (137.75 ± 23.75 μg/day)
Description: This study was a longitudinal study in an academic center, with a follow-up period of 6 months. Ten patients with well-differentiated thyroid carcinoma eligible for surgical treatment and subsequent radioactive iodine ablation therapy were studied in a hypothyroid state after thyroidectomy and in a subclinical hyperthyroid state (TSH-suppression according to standard treatment protocol).

Intervention type: OTHER
Group type: OTHER
Intervention: Levothyroxine therapy (137.75 ± 23.75 μg/day)
Description: This study was a longitudinal study in an academic center, with a follow-up period of 6 months. Ten patients with well-differentiated thyroid carcinoma eligible for surgical treatment and subsequent radioactive iodine ablation therapy were studied in a hypothyroid state after thyroidectomy and in a subclinical hyperthyroid state (TSH-suppression according to standard treatment protocol).
Study: NCT01834144

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Training
Study: NCT04378309

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ePREP
Description: 6-session online psychoeducational program with supporting coach calls
Study: NCT03342391

Intervention type: OTHER
Group type: OTHER
Intervention: Transnasal esophagoscopy
Description: single food antigen introduction OR removal of topical swallowed steroid therapy followed by surveillance utilizing TNE
Study: NCT01740440

Intervention type: DEVICE
Group type: OTHER
Intervention: BMR Face
Description: BMR Face used in accordance with manufacturer IFU
Study: NCT02426372

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QBECO SSI
Description: QBECO Site Specific Immunomodulators

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QBECO SSI
Description: QBECO Site Specific Immunomodulators

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QBECO SSI
Description: QBECO Site Specific Immunomodulators
Study: NCT03065504

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Turmeric

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Turmeric-containing combination tablet

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablets
Study: NCT02825264

Intervention type: DEVICE
Intervention: STARflo Implant
Description: All patients who have been implanted with STARflo implant from 2011 will be offered to participate to this data collection
Study: NCT04322630

Intervention type: OTHER
Intervention: Change in Soluble MER Concentration
Description: Measuring change in soluble MER Concentration post compared to pre bypass for each patient.
Study: NCT03584490

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phone Administration of Questionnaires
Description: This intervention will pilot questionnaire administration over the phone with currently enrolled or previously enrolled participants from the original intervention. This method was used during the COVID-19 pandemic.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Phone Administration of Questionnaires
Description: This intervention will pilot questionnaire administration over the phone with currently enrolled or previously enrolled participants from the original intervention. This method was used during the COVID-19 pandemic.
Study: NCT03870100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Pharmaceutical form: water injection Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Pharmaceutical form: water injection Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Pharmaceutical form: water injection Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Pharmaceutical form: water injection Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Pharmaceutical form: water injection Route of administration: subcutaneous
Study: NCT02418429

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: waxy maize starch
Description: pancake test meal with waxy maize starch only

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: waxy maize starch
Description: pancake test meal with waxy maize starch only

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: waxy maize starch and Whey Protein
Description: pancake test meal with waxy maize starch and whey protein

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resistant Starch
Description: pancake test meal with resistant starch only

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resistant Starch
Description: pancake test meal with resistant starch only

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: resistant starch and whey protein
Description: pancake test meal with resistant starch and whey protein
Study: NCT00647894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alprazolam Extended-Release Tablets 1 mg
Study: NCT03300284

Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: Quality of Life Questionnaires
Study: NCT03474861

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anticancer medication A01; immune cells IC01
Description: The administration of the anticancer medication A01 and immune cells IC01 will be performed in The Second Hospital of Jiaxing, Zhejiang, China.~The subjects will be observed for any side effects during this time and all the adverse events will be recorded.
Study: NCT04382300

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pyrotinib combined with thalidomide
Description: Single Group Assignment
Study: NCT02391701

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet
Description: diet program 1 day a month for 3 months in 120-minute diet sessions + freely receive Atlantic Diet food (vegetables, cheese, olive oil, mussels and wine)
Study: NCT02835742

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sargramostim

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04711434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 Antibody
Description: Toripalimab: 240mg IV every 3 months for a year
Study: NCT04525352

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RP-L401
Description: CD34+ enriched hematopoietic stem cells from pediatric subjects with infantile malignant osteopetrosis transduced ex vivo with lentiviral vector carrying the TCIRG1 transgene
Study: NCT05614232

Intervention type: RADIATION
Intervention: Chest X-ray
Description: Chest radiographs

Intervention type: RADIATION
Intervention: Chest X-ray
Description: Chest radiographs
Study: NCT00647894

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xanax XR Tablets 1 mg
Study: NCT02910024

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Magstim Super Rapid2 System, intermittent theta-burst-stimulation (iTBS) protocol
Description: iTBS applied over ipsilesional M1
Study: NCT01195246

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HEPLISAV
Description: Intramuscular (IM) injection on Day1

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Engerix-B
Description: Intramuscular (IM) injection on Day 1

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fendrix
Description: Intramuscular (IM) injection on Day 1
Study: NCT03459170

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BPX-501 T cells
Description: Biological: T cells transduced with CaspaCIDe® safety switch

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rimiducid
Description: administered to eliminate BPX-501 cells in the event of GVHD
Study: NCT03385200

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SonoVue
Description: As part of the study therapy supportive ultrasound will be performed with iv Infusion of the chemotherapeutic agent.
Study: NCT04465071

Intervention type: DRUG
Group type: OTHER
Intervention: AEONTM Repair and AEONTM Protect Plus lubricating eye drops
Description: AEONTM Repair and AEONTM Protect Plus lubricating eye drops
Study: NCT02707107

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous infusions of WCK 5222

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01813188

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ABM seeded onto a porous TCP and DBM
Description: cells collection under sedation . 114 mL are obtained and processed through a ficoll gradient.~Autologous bone marrow (ABM) cells seeded onto a porous tricalcium phosphate ceramic (TCP) and demineralized bone matrix (DBM)
Study: NCT01582945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine IV 0.5mg/kg infusion twice a week for 3 weeks as augmentation of ongoing antidepressant regimen
Study: NCT01813188

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: autologous bone graft
Description: autologous bone graft
Study: NCT02910024

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Magstim Super Rapid2 System, sham-stimulation (in iTBS)
Description: iTBS applied with tilted coil over parieto-occipital vertex
Study: NCT02025322

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Mentoring
Description: Participants in the Peer Mentoring arm will be paired with a Peer Mentor for the duration of the 4-month intervention. Peer Mentors are HIV-positive patients who demonstrate high levels of medication and treatment adherence and are knowledgeable about HIV/AIDS and barriers to care. During the 4-month intervention, Peer Mentors will contact participants weekly via in-person, phone, or email, with the option to provide more frequent contact, if needed. Peer Mentors will provide social support and remind participants to take their medications and attend upcoming medical appointments.~Study participants will also attend four monthly, one hour workshops on HIV/AIDS, medication adherence, health literacy, and health and wellness, which will be developed and co-facilitated by Peer Mentors.
Study: NCT01545674

Intervention type: PROCEDURE
Intervention: Blood Draw
Description: Blood will be drawn from the mother and father
Study: NCT00574886

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Id-KLH
Description: Idiotype vaccine - .5mg recombinant idiotype immunoglobulin protein given subcutaneously for a total of five administrations over 6 months.
Study: NCT02647749

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardioinsight® mapping system

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardioinsight® mapping system

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardioinsight® mapping system

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional method without non-invasive mapping

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional method without non-invasive mapping
Study: NCT01913717

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External beam radiotherapy
Description: The patients will be treated with extreme hypofractionated radiotherapy with the dose delivery system that will result most fit at the in-silica study. Simultaneous Integrated Boost (SIB) technique will be applied to deliver a total dose of 36.25 Gy in 5 fractions (over 10 days) to the whole prostate (7.25 Gy/fraction) and 37.5 Gy to the dominant intraprostatic lesion DIL (7.5 Gy/fraction), profiting of the high sensibility of prostate cancer to high dose/fraction. Several strategies will be applied in order to reduce the dose to the surrounding organs at risk.
Study: NCT02647749

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional method without non-invasive mapping
Study: NCT03897309

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VXA-G1.1-NN
Description: Monovalent GI.1 tableted vaccine
Study: NCT02084693

Intervention type: DEVICE
Intervention: COMPREHENSIVE
Description: Comprehensive® Reverse Shoulder products are indicated for use in patients whose shoulder joint has a grossly deficient rotator cuff with severe arthropathy and/or previously failed shoulder joint replacement with a grossly deficient rotator cuff.
Study: NCT03897309

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VXA-G1.1-NN
Description: Monovalent GI.1 tableted vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VXA-G2.4-NS
Description: Monovalent GII.4 tableted vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VXA-G2.4-NS
Description: Monovalent GII.4 tableted vaccine
Study: NCT02672800

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: the Reclaiming Yourself tool
Description: This tool is a behavioural writing intervention, intended to facilitate bereavement for spousal caregivers of persons with dementia
Study: NCT01322659

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Helmet
Description: Weaning from mechanical ventilation with noninvasive positive pressure ventilation delivered by means of the helmet

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Endotracheal tube
Description: Weaning from mechanical ventilation with invasive mechanical ventilation delivered by means of the endotracheal tube
Study: NCT02107404

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic Cells DCVAC/PCa
Description: DCVAC/PCa Experimental therapy
Study: NCT00766025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin Calcium
Description: single oral dose on days 1, 4, 5, 6, 10-16, 17
Study: NCT02974478

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Orange juice with meals
Description: orange juice (20% of energy requirement/day)
Study: NCT00541086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anastrozole
Description: 1 mg per day, orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: anastrozole
Description: 1 mg per day, orally
Study: NCT03897309

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo Tablets
Description: Tablets matching in number and appearance to active vaccine doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo Tablets
Description: Tablets matching in number and appearance to active vaccine doses

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Tablets
Description: Tablets matching in number and appearance to active vaccine doses
Study: NCT00541086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exemestane
Description: 25 mg per day, orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: exemestane
Description: 25 mg per day, orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole
Description: 2.5 mg per day, orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: letrozole
Description: 2.5 mg per day, orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tamoxifen citrate
Description: 20 mg per day, orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tamoxifen citrate
Description: 20 mg per day, orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tamoxifen citrate
Description: 20 mg per day, orally
Study: NCT00386893

Intervention type: PROCEDURE
Group type: OTHER
Intervention: simultaneous EEG/fMRI
Description: fMRI/EEG recordings

Intervention type: DEVICE
Group type: OTHER
Intervention: fMRI